Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis

Jan Willem C. Alffenaar, Tawanda Gumbo, Kelly E. Dooley, Charles A. Peloquin, Helen McIlleron, Andre Zagorski, Daniela M. Cirillo, Scott K. Heysell, Denise Rossato Silva, Giovanni Battista Migliori

Research output: Contribution to journalReview articlepeer-review

Abstract

Tuberculosis (TB) elimination requires innovative approaches. The new Global Tuberculosis Network (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in the field of TB elimination using multidisciplinary, multisectorial approaches. The TB Pharmacology section within the new GTN aims to detect and study the current knowledge gaps, test potential solutions using human pharmacokinetics informed through preclinical infection systems, and return those findings to the bedside. Moreover, this approach would allow prospective identification and validation of optimal shorter therapeutic durations with new regimens. Optimized treatment using available and repurposed drugs may have an increased impact when prioritizing a personcentered approach and acknowledge the importance of age, gender, comorbidities, and both social and programmatic environments. In this viewpoint article, we present an in-depth discussion on how TB pharmacology and the related strategies will contribute to TB elimination.

Original languageEnglish (US)
Pages (from-to)1734-1780
Number of pages47
JournalClinical Infectious Diseases
Volume70
Issue number8
DOIs
StatePublished - Apr 15 2020

Keywords

  • Drug resistance
  • Pharmacodynamics
  • Pharmacokinetics
  • Therapeutic drug monitoring
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis'. Together they form a unique fingerprint.

Cite this